profound clinical consequences [6] [7] [8] [9] [10] , affecting the whole dialysis population including children [11] [12] [13] [14] .
Vascular calcification can generally be promoted by multiple factors [2] , including a number of drugs (e.g. dexamethasone [15] and vitamin K antagonists [16, 17] ), altered mineral homeostasis (e.g. in hypercalcaemia [18] and hyperphosphataemia [19] ) and inflammation {e.g. elevated levels of inflammatory cytokines tumor necrosis factor-alpha (TNF-a), interleukin-1 (IL-1) and IL-6 [2, 20] }. Importantly, many calcification-accelerating factors are associated with a state of uraemia and serum drawn from uraemic patients on chronic dialysis promotes vascular calcification in vitro [21, 22] . The exact mechanism underlying these procalcifying effects is not clear yet, since uraemic toxins represent a very large and heterogeneous group of molecules [23] .
Characteristic for vascular calcification is the maladaptation and osteoblastic transition of vascular smooth muscle cells (VSMCs) [2, 14] , leading to mineralized extracellular matrix (ECM) formation in the vasculature. Shanahan [14] recently described this to be a three-step process, being initiated by uraemic toxin-mediated damage to the contractile VSMCs that can regulate the vessel tone, followed by acquisition of a synthetic VSMC phenotype specialized on adaption and repair, eventually leading to osteochondrocytic VSMCs promoting calcification by deposition of nanocrystals. Although it is now well documented that uraemic toxins drive VSMC damage and phenotypic changes that promote vascular calcification [14] , the exact molecular mechanisms underlying this phenomenon are still rather poorly understood to date.
Many haemodialysis patients exhibit chronic microinflammation with elevated serum levels of TNF-a and IL-6 [24] [25] [26] [27] . The size of these uraemic toxins exceeds the molecular cut-off point of conventional dialysis membranes and they are thus not effectively cleared from the blood [28] . Both TNF-a and IL-6 levels correlate with cardiovascular mortality and vascular calcification [24, [29] [30] [31] and IL-6 is a robust predictor of cardiovascular events and a known inducer of vascular calcification in dialysis cohorts [24, [31] [32] [33] [34] [35] [36] [37] [38] . Both cytokines are key inflammatory mediators for immune and stromal cell types such as monocytes, endothelial cells, osteoblasts, mesenchymal stromal cells (MSCs) and VSMCs [39] [40] [41] [42] [43] [44] and TNF-a has been previously identified as an inducer of IL-6 expression in VSMCs [45] . However, the cause of elevated serum TNF-a and IL-6 levels, their relationship in the context of uraemia and underlying signalling events are not yet fully understood.
Previous analysis on major transcriptional regulatory sites in the IL-6 promoter region indicated a functional role of nuclear factor jB (NF-jB) and activator protein 1 (AP-1)-signalling for IL-6 induction [46] . In prior whole-genome analysis of perivascular MSCs from late-stage type 1 diabetes patients with renal failure we indeed found upregulation of IL-6 and immediate early response gene c-FOS [47] , but no change in NFjB, compared with cells from healthy controls or early-stage patients without renal failure. This points to c-FOS-and IL-6-mediated responsiveness of vasculature resident cells to the uraemic milieu [47, 48] . c-FOS encodes a 62-kDa protein involved in formation of the AP-1 signalling transcription factor complex, which in turn binds to the promoter regions of respective target genes (e.g. IL-6), thus converting extracellular stimuli (e.g. TNF-a) into discrete changes of gene expression (e.g. increased transcription of the IL-6 gene) [48, 49] .
In this article we have assessed in detail the molecular mechanisms underlying uraemic toxin and, in particular, TNF-ainduced IL-6 production in VSMCs and its important influence on osteoblastic transition and vascular calcification.
M A T E R I A L S A N D M E T H O D S

Materials
Chemicals were purchased from Sigma (St Louis, MO, USA), cell culture plastics from Becton Dickinson (Falcon, Franklin Lakes, NJ, USA), culture media and buffers from Biochrom AG (Berlin, Germany) and foetal calf serum (FCS) from Invitrogen (Darmstadt, Germany). Human recombinant TNF-a, SR-11302 (inhibitor of AP-1 complex) and PD-184352 [extracellular signal-regulated kinases (ERK) inhibitor] were purchased from Tocris Bioscience (Wiesbaden, Germany), the anti-TNF-a blocking antibody infliximab from Hospira (Lake Forest, IL, USA), the anti-IL-6 blocking antibody (MAB206) and immunoglobulin G (IgG) isotype control (MAB002) from R&D Systems (Minneapolis, MN, USA) and the small interfering RNA (siRNA) reagent against c-FOS (sc-29221) or scrambled siRNA control (sc-37007) from Santa Cruz Biotechnology (Heidelberg, Germany).
Clinical serum samples
Uraemic serum samples were obtained from 14 patients (Table 1 ; average age 70 6 13.7 years, six males and eight females) undergoing haemodialysis in the Permeability Enhancement to Reduce Chronic Inflammation (PERCI)-I trial at the dialysis center of the Charité University Hospital Berlin, with permission from the local ethics committee [28] . Patients were excluded from the study if they were unable to give informed consent, used immunosuppressive medication, were pregnant or breastfeeding or had a C-reactive protein (CRP) >50 mg/L or serum albumin <35 g/L at the pre-study visit. To prepare uraemic serum, blood samples were collected from study participants after a run-in phase of 3 weeks with high-flux haemodialysis prior to the first dialysis session and human serum separated by centrifugation at 2000 g for 15 min and then stored at À80 C. To obtain a uraemic serum pool (USP), serum samples of these 14 patients were pooled at equal volumes. As a negative control, a non-uraemic healthy serum pool (HSP) was prepared from 14 healthy individuals at our nephrology department (average age 36 6 9.2 years, nine males and five females).
Cell culture and viability assessment
Human coronary artery media calcifying VSCMs were purchased from Lifeline Cell Technology (Frederick, MD, USA) and kept in corresponding VascuLife culture medium with growth supplements. The cells were isolated from a single donor (male, African American, 18 years old), characterized by immunostaining for alpha-SMA and used between passages 2 and 6. Cell viability was assessed by measuring mitochondrial Regulation of VSMC calcification by uraemic serum activity with the water-soluble tetrazolium (WST-8) salt assay (PromoCell, Heidelberg, Germany).
VSMC calcification assay
Calcification was induced with an ossification medium (OM) [22] containing 1.58 mM calcium gluconate, 0.1 lM dexamethasone, 0.5 mM ascorbic acid and 2.5 mM betaglycerol phosphate in basic VSMC culture medium. To study the influence of uraemic serum on cell differentiation, the OM was supplemented with either 5% USP, 5% HSP or 5% FCS (Invitrogen), with or without stimulant (TNF-a 1 ng/mL) or inhibitors (SR-11302, 10-1000 nM; PD-184352, 100 nM and anti-IL-6, anti-TNF-a or respective isotype control antibody, all three employed at 10 lg/mL).
Calcium deposition in ECM secreted by VSMC was assessed with Alizarin Red S staining (Sigma), which binds with calcium ions. After 10 days of incubation with OM or control medium, the cells were fixed with 2% paraformaldehyde, stained with 1% Alizarin Red S and the culture plates photographed under a light microscope. The degree of calcification was assessed using the Alizarin Red Staining Quantification Assay (ARed-Q, ScienCell Research Laboratories, Corte Del Cedro Carlsbad, CA, USA). Calcium quantification in samples was performed with o-cresophtalein complexone (Sigma Aldrich) upon calcium extraction with hydrochloric acid and normalized to respective protein content upon protein extraction with 10% sodium hydroxide and 1% sodium dodecyl sulphate.
Gene expression analysis
The expression of different target genes was assessed with reverse transcription and quantitative real-time polymerase chain reaction (qRT-PCR). Total RNA was extracted with the PerfectPure RNA Cultured Cell Kit (5Prime; Hamburg, Germany), concentration and purity of the RNA were estimated by spectrophotometry (Nanodrop, Thermo Fisher) and reverse transcribed into cDNA using random hexamer primers as described previously [50] .
The qRT-PCR was performed on the 7500 Fast Block (Applied Biosystems, Darmstadt, Germany). The primer sequences for IL-6 (GenBank NM_000600.3), runt-related transcription factor-2 (RUNX2) (NM_001024630.3), alkaline phosphatase (ALP) (NM_001632.4), collagen type I subunit a1 (COL1A1) (NM_000088.3), collagen type II subunit a1 (COL2A1) (NM_001844.4), matrix metalloproteinase 2 (MMP2) (NM_004530.5), cytochrome b-245 beta chain (NOX2) (NM_000397.3) and housekeeping genes B2M (NM_004048.2), GAPDH (AF261085.1) and YWHAZ (NM_001135699.1) are summarized in Supplementary data, Table S1 . After an initial activation step for 2 min at 50 C and denaturation at 95 C for 10 min, 40 cycles of 15 s at 95 C and 1 min at 60 C were performed. The specificity of the reaction was verified by melting curve analysis at the end of each series of assays. The relative amount of gene transcript was calculated with the cycle threshold method by using the Applied Biosystems 7500 System v.1.2.3 software and normalized for the endogenous reference b2-microglobulin [50] .
DNA constructs and reporter plasmids
Genomic DNA from VSMCs isolated via Isol-RNA Lysis Reagent solution (5Prime) was used to generate progressive IL-6 5 0 -deletion luciferase plasmid constructs (pLuc 2211, pLuc 1211, pLuc 611 and pLuc 171) via PCR amplification with the respective primer pairs. The Infusion Cloning Kit (Clontech; Takara Bio USA, Mojntain View, CA, USA) was used with the pGL4.10 vector backbone to create the luciferase reporter constructs. The correct length of the promoter segments was checked by restriction digestion and by sequencing (LC Genomics, Houston, TX, USA).
Transient transfection and luciferase assays
For transient transfection studies, cells were seeded into sixwell culture plates at a density that allowed them to reach 70-80% confluence after 24 h and transfections were performed by using the TurboFect transfection reagent (Fermentas, Darmstadt, Germany) in the absence of serum with Turbofect-DNA at a ratio of 1 mL/0.33 mg.
The VSMCs were transfected with the IL-6 reporter plasmid (0.2 lg/well) and cotransfected with the reference pRL-TK Renilla plasmid (0.02 lg/well). Luciferase activity was assessed with the dual-luciferase reporter assay system (Promega, Mannheim, Germany) with a microplate luminometer (Fluostar Optima; BMG Labtech, Ortenberg, Germany) and normalized to background levels of Renilla luciferase activity from the cotransfected control vectors. Transfection of VSMCs with either siRNA for c-FOS (sc-29221) or scrambled siRNA control (sc-37007) was performed with the siRNA Transfection Reagent (all from Santa Cruz Biotechnology). For computational analysis of the human IL-6 promoter, the region -599 to -161 (GenBank NC_000007.14) was analysed with Transcription Element Search Software (http://www.cbil. upenn.edu/cgi-bin/tess/tess) to predict and locate potential transcription factor binding sites.
Nuclear extracts and electrophoretic mobility shift assay
Nuclear extracts were prepared by using the NE-PER Nuclear and Cytoplasmic Extraction Kit and oligonucleotide probes labelled with the Biotin 3 0 -End DNA Labeling Kit (both from ThermoFisher Scientific, Waltham, MA, USA). For the electrophoretic mobility shift assay (EMSA) [50] , the following probe was used (IL-6 promoter region given in parenthesis): AP-1: 5 0 -CAAAGTGCTGAGTCACTAATAA-3 0 (-278 to -257). Each binding mixture (20 lL) for the EMSA contained 5 lg of nuclear extract, 20 fmol of labelled double-stranded probe, 1 lg of poly(deoxyinosinicdeoxycytidylic) acid and 2 ll of 10Â reaction buffer and was incubated at room temperature for 30 min. In supershift experiments, nuclear extracts were incubated with c-FOS antibody (Active Motif, Rixensart, Belgium) for 20 min at room temperature before the addition of the biotin-labelled probe. The protein-DNA complexes were then analysed by electrophoresis in 6% non-denaturing polyacrylamide gels and visualized using the LightShift Chemiluminescent EMSA Kit (ThermoFisher Scientific).
Cytokine measurements and protein detection with western blot
TNF-a and IL-6 protein concentrations were measured using human TNF-a or IL-6 Antibody Pair Kits according to the manufacturer's instructions (ThermoFisher Scientific) and explained in detail elsewhere [50, 51] . The lower limit of detection was 2 pg/mL as indicated in the product specification by ThermoFisher Scientific.
Cell extracts for western blot were prepared as described earlier [52] , electrophoresed on SDS-polyacrylamide gels, western blotted and detected using primary antibodies (Supplementary data, Table S2 ) against c-FOS/AP-1, RUNX2, COL2A1 and GAPDH (supplier as outline in Supplementary data, Table S2 ), and secondary peroxidase-conjugated IgG (Dianova, Hamburg, Germany). The bands were visualized/ quantified using the Enhanced Chemiluminescence Detection System (ThermoFisher) and Image J 1.43 software (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.00 (GraphPad Software, La Jolla, CA, USA). Paired t-test was used for pairwise comparisons and in case of multiple variables repeated measures analysis of variance (ANOVA) was used in combination with Student-Newman-Keuls post hoc test or Kruskal-Wallis with Müller-Dunn post hoc test. The results are expressed as means 6 SD and non-parametric data are presented as medians. A P-value <0.05 was considered significant.
R E S U L T S
TNF-a and IL-6 levels in uraemic serum of haemodialysis patients Previous studies have indicated that uraemic serum from haemodialysis patients may contain higher levels of the proinflammatory TNF-a and IL-6 [24, 26, 27, 53, 54] .
In agreement with these earlier studies, we could indeed detect elevated concentrations of TNF-a and IL-6 in the sera from uraemic patients compared with healthy controls ( Figure 1A) . The mean TNF-a level in uraemic serum was 93 pg/mL compared with 35 pg/mL in healthy serum (P < 0.05) and the mean IL-6 level in corresponding uraemic and healthy patient serum was 19 pg/mL and 7 pg/mL (P < 0.05), respectively.
Effect of uraemia and TNF-a on IL-6 levels in VSMCs cultured in vitro
We thus studied whether and how uraemic serum and, in particular, TNF-a in uraemic serum could upregulate the expression of the pleiotropic inflammatory activation marker IL-6 in VSMCs and thus may contribute the micro-inflammation in haemodialysis patients.
Addition of 5% USP to the culture medium stimulated IL-6 mRNA expression in VSMCs to a higher degree than addition of the same concentration of 5% HSP or 5% FCS standard cell culture supplement (both P < 0.001; Figure 1B) . Importantly, the very strong increase in IL-6 mRNA expression was substantially reduced in the presence of the specific TNF-a blocker infliximab (P < 0.001).
To investigate how TNF-a impacts the activity of the IL-6 gene promoter, VSMCs were transfected with IL-6 reporter gene constructs. Stimulation with TNF-a resulted in increased IL-6 promoter activity at 6-12 h (P < 0.01; Figure 1C ) and IL-6 protein release at 6-24 h post-stimulation (all P < 0.01; Figure 1D ), and IL-6 promoter activity was abolished by different doses (10, 50 and 100 lg/mL) of infliximab (P < 0.05; Figure 1E ).
Activation of IL-6 gene promoter by TNF-a stimulation
To identify the IL-6 promoter regions mediating the response to TNF-a signalling, we generated functional 5 0 -deletions of the IL-6 promoter and transiently transfected VSMCs with these constructs in order to assess their responsiveness to TNF-a (Figure 2) .
While the full-length construct and the two constructs with truncations in promoter region -1200 and -600 maintained full responsiveness to TNF-a (P < 0.05; Figure 2A) , truncation of the promoter region spanning the positions -559 to -161 resulted in a complete functional loss of IL-6 promoter activity (no difference to resting controls).
This result generally suggests that the identified region comprises essential regulatory elements for IL-6 promoter activity. In fact, our subsequent computational in silico analysis predicted that this promoter region contains a high-affinity AP-1 binding site at position -264 for the transcription factor c-FOS.
Activation of the transcription factor c-FOS by TNF-a
To validate the potential involvement of c-FOS in TNF-ainduced IL-6 promoter activation, EMSA was performed ( Figure 2B ) by using biotin-labelled double-stranded oligonucleotides targeting the calculated AP-1/c-FOS binding positions -278 to -257 of the corresponding IL-6 promoter region.
First, nuclear extracts of VSMCs stimulated with TNF-a formed a prominent DNA-protein complex with a consensus oligonucleotide for c-FOS binding, which was clearly distinguishable as a strong band distinct from the free probe.
To verify the specificity of c-FOS binding, the EMSA was performed with a 100-fold molar excess of an unlabelled c-FOS consensus oligonucleotide. This competition assay inhibited Regulation of VSMC calcification by uraemic serum formation of the c-FOS-DNA complex. In turn, the presence of a specific anti-c-FOS antibody led to a supershift of the DNAprotein complex.
Uraemia and TNF-a promote IL-6 expression in VSMCs through AP-1/c-FOS signalling
To study the response of VSMCs to a uraemic milieu, the VSMCs were incubated with pooled uraemic serum or the key uraemic mediator TNF-a and studied for c-FOS protein and IL-6 mRNA expression in the presence or absence of specific inhibitors.
First, VSMC exposure to 5% USP led to a strong 5-fold increase in c-FOS protein expression (P < 0.01; Figure 3A ) that could be efficiently blocked by siRNA directed against c-FOS (P < 0.01) but not by the scrambled siRNA-negative control.
USP exposure of VSMCs also induced a 10-fold increase in IL-6 mRNA expression (P < 0.001; Figure 3B ) that could be efficiently blocked by SR-11302 (P < 0.001), an effective inhibitor of the c-FOS-containing AP-1 transcription factor. Similarly, treatment of VSMCs with the uraemic mediator TNF-a led to strong induction of IL-6 mRNA (P < 0.001), which could again be effectively blocked by the SR-11302 inhibitor (P < 0.01).
Taken together with the inhibitory effects of TNF-a blocker infliximab on IL-6 induction ( Figure 1B and E), these findings suggested that the stimulation of IL-6 in VSMCs by uraemic serum was induced by TNF-a and mediated through c-FOS.
TNF-a in uraemic serum promotes osteoblastic transition and calcification of VSMCs via ERK and AP-1/c-FOS-mediated induction of IL-6 expression
We next studied if the uraemia and TNF-a-induced and c-FOS/AP-1-pathway-mediated induction of IL-6 expression could affect the osteoblastic transition and consequent calcification of VSMCs in a pro-osteogenic environment rich in calcium and phosphate to promote the formation of mineralized ECM (Figures 4 and 5, respectively) .
In agreement with earlier findings, we also found a significant upregulation of IL-6 mRNA in VSMCs in the presence of 5% USP compared with 5% HSP control (P < 0.001; Figure 4A ), when in contact with osteogenic induction medium for 6 days, to monitor the early events of osteogenic transition in VSMCs.
The induction of IL-6 mRNA could be strongly ameliorated by the addition of blocking antibody towards TNF-a or by the addition of selective inhibitors towards ERK (PD-184352) and AP-1 (SR-11302) (all three P < 0.001; Figure 4A ), thus FIGURE 1: TNF-a in uraemic serum induces IL-6 expression in VSMCs. (A) TNF-a and IL-6 levels (pg/mL) in sera derived from healthy subjects or haemodialysis patients (n ¼ 14), which were used to generate the HSP and USP. (B) Induction of IL-6 mRNA expression (AU; arbitrary units, n ¼ 6) in VSMCs in response to a 6-h stimulation with either 5% HSP or 5% USP, or 5% FCS negative control, and 5% USP with TNF-a blocking antibody infliximab (10 lg/mL). Kinetic monitoring (6, 12, 24 and 48 h) of (C) IL-6 promoter activity (RLU; relative luciferase activity, n ¼ 4) and (D) IL-6 protein release (pg/mL, n ¼ 6) in VSMCs transfected with full-length IL-6 luciferase reporter construct and stimulated for 6 h with TNF-a (10 ng/mL) and unstimulated resting controls and (E) IL-6 promoter activity (RLU, n ¼ 6) in VSMCs stimulated for 6 h with TNF-a (10 ng/mL) in the presence of infliximab (0, 10, 50 and 100 lg/mL). Mean 6 SEM, with *P < 0.05, **P < 0.01 and ***P < 0.001.
indicating that the USP and TNF-a-dependent induction of IL-6 in VSMCs is mediated via an ERK and AP-1-dependent signalling pathway.
The VSMCs also demonstrated upregulation of a panel of transcripts characteristic for osteochondroblastic transition and oxidative stress (all P < 0.001; Figure 4B ), such as RUNX2, ALP, COL1A1, COL2A1, MMP2 and NOX2, when subjected to osteogenic differentiation in the presence of 5% USP compared with 5% HSP.
Importantly, in line with the observed reduction in IL-6 mRNA, the induction of these characteristic markers for osteoblastic transition and oxidative stress could be ameliorated by supplementation of ERK and AP-1 inhibitors (PD-184352 and SR-11302; both P < 0.001; Figure 4B ) and by blocking antibodies towards TNF-a and IL-6 (both P < 0.001) but not by the corresponding isotype control antibody. Furthermore, the induction of the key osteoblastic transition markers RUNX2 and COL2A1 in response to 5% USP compared with 5% HSP could also be confirmed on a proteomic level with western blot (Figure 4C ), which could again be abrogated by blocking antibodies towards TNF-a and IL-6 but not by control antibody.
In accordance with the observed gene expression changes, a 10-day osteogenic differentiation of VSMCs in the presence of 5% USP induced a strong 4.5-fold increase in the deposition of calcified ECM compared with differentiation in the presence of 5% HSP (mean 347 versus 77 lg calcium/mg protein, respectively; P < 0.01; Figure 5A ), which could be strongly reduced by the addition of blocking antibodies towards TNF-a and IL-6 (102 and 144 lg calcium/mg protein, 3.4-and 2.4-fold reduction, respectively; both P < 0.05) but not by the addition of isotype control antibody (330 lg calcium/mg protein).
Supplementation of 1 ng/mL of TNF-a to differentiation media also promoted a 3-fold increase relative to FCS control (data not shown) in the deposition of calcified ECM by VSMCs (242 lg calcium/mg protein, P < 0.01), while concomitant addition of anti-IL-6 antibody led to a 50% reduction in calcified ECM (123 lg calcium/mg protein, P < 0.05), thus identifying not only TNF-a, but also induction of IL-6 production by VSMCs, as major mediators of uraemic serum pro-calcifying activity.
The strong increase in the deposition of calcified ECM in response to osteogenic differentiation with 5% USP was 0 -deletions (full-length -2200 construct, and -1200, -600 -160, and þ11 deletion) and the relative luciferase activity (RLU, n ¼ 4) determined in cells stimulated for 6 h with TNF-a (10 ng/mL) or in unstimulated resting control cells, demonstrating a functional loss in IL-6 promoter activity upon truncation of the promoter region spanning the positions -559 to -161, and concomitant identification of a potential high affinity AP-1-binding site at position -264 with computation analysis; and (B) Validation of the AP-1 transcription factor-binding site with the EMSA (one representative experiment shown) by using biotin-labelled double-stranded oligonucleotides targeting to the calculated AP-1/c-FOS positions -278 to -257 of the corresponding IL-6 promoter region. VSMCs were stimulated for 6 h with TNF-a (10 ng/mL) and nuclear fractions analysed for formation of nuclear complexes with c-FOS probe either in the presence of 100-fold molar excess of unlabelled (competitor) IL-6 DNA (reduced shift-a lower arrow) or in the presence of a c-FOS-specific antibody (supershift-an upper arrow). Mean 6 SEM, with *P < 0.05.
Regulation of VSMC calcification by uraemic serum accompanied by an 8-fold increase in ALP activity (P < 0.001; Figure 5B ), a key enzyme promoting ECM calcification, which was again substantially reduced by the addition of blocking antibody towards IL-6 (60% reduction, P < 0.01), but not by the corresponding isotype control antibody (not significant).
Importantly, supplementation of different concentrations of AP-1 inhibitor SR-11302 to 5% USP led to a dose-dependent reduction in pro-calcifying activity (10 nM: 284 versus 100 nM: 214 versus 1000 nM: 97 lg/mg; P < 0.05 and P < 0.001, respectively; Figure 5C ) and compared to dimethyl sulphoxide (DMSO) vehicle (10 nM: 284 versus 318 lg/mg, not significant; 100 nM: 214 versus 318 lg/mL, P < 0.05; and 1000 nM: 97 versus 285 lg/mg, P < 0.001).
Furthermore, VSMC viability was strongly reduced for differentiation in the presence of 5% USP compared with 5% HSP (29% versus 76% viable, P < 0.001; Supplementary data, Figure S1A ), but the loss in viability could be ameliorated by the addition of anti-TNF-a (29% versus 55% viable, P < 0.01) and anti-IL-6 (29% versus 56% viable, P < 0.01) but not by control antibody (36% viable). VSMCs undergoing differentiation in the presence of 1000 nM of SR-11302 had improved viability compared with 1000 nM DMSO control (64% versus 41% viable, P < 0.001; Supplementary data, Figure S1B ), going in hand with the most protective effect against vascular calcification ( Figure 5C ).
Taken together, these data indicate that interference with AP-1/c-FOS signalling or direct targeting of uraemic toxins, such as TNF-a and IL-6, may mediate protective effects on cell viability and substantially antagonizes VSMC calcification.
D I S C U S S I O N
Our study demonstrates that uraemic serum-induced osteoblastic transition and vascular calcification is mediated through TNF-a, IL-6 and AP-1/c-FOS signalling (Figure 6 ), identifying for the first time the contribution of AP-1/c-FOS signalling in biomineralization of human VSMCs. Our results show in detail the molecular pathomechanisms that link inflammation and vascular calcification, emphasize the pathogenic role of inflammatory cytokines and offer novel targets for therapeutic intervention.
To our knowledge, there is only one prior study to date [55] that investigated a direct relationship between TNF-a and AP-1 signalling in osteoblastic transition and calcification of cells originating from the vascular wall. This study was conducted with vascular media cells of bovine origin but not in primary human coronary artery media calcifying VSMCs, which resemble a more relevant model for therapeutic intervention in human patients.
A recent paper emphasized that although a general biomineralization-related mimicry exists (e.g. between MSCs, osteoblasts or vascular calcifying cells), the mechanisms, signalling pathways and gene regulation can differ dramatically depending on the species, tissue origin and anatomic location of studied cell types [56] .
Prior studies in a murine calvaria osteoblastic cell line have identified AP-1/FRA-2 and JUN-D as regulators of biomineralization [57, 58] . The contribution of ERK and AP-1 in osteogenic differentiation has also been described in human bone marrow-derived MSCs [59] . In contrast to human VSMCs, this appears to be AP-1/c-JUN but not c-FOS specific [60] .
As outlined in the "Introduction" section, it is already well known that IL-6 and TNF-a are elevated in uraemia [24, 26, 27, 53, 54] and that the level of these pro-inflammatory cytokines correlates with cardiovascular morbidity and mortality and vascular calcification [24, [29] [30] [31] [32] [33] [34] [35] [36] [37] . A direct relationship between TNF-a and IL-6 in biomineralization has been demonstrated for the calvaria cell line [61] , where it was mediated via NF-jB signalling [62] .
We show that TNF-a and IL-6 are key pro-inflammatory components in uraemic serum with a direct impact on human VSMC calcification. Importantly, we demonstrate that uraemic TNF-a further promotes IL-6 production in VSMCs, resulting from AP-1/c-FOS-mediated activation of the IL-6 promoter, thus leading to strong amplification of osteoblastic transition and consequent biomineralization in human VSMCs.
Our novel finding on AP-1/c-FOS-mediated induction of osteoblastic transition and biomineralization of VSMCs in VSMCs upon a 1-h pretreatment of cells with either c-FOS siRNA or scrambled siRNA, followed by a 3-h stimulation with 5% USP; and (B) blocking of IL-6 mRNA upregulation (AU, n ¼ 6) in VSMCs in response to a 6-h stimulation with either 5% USP or TNF-a (10 ng/ mL) following a 1-h pretreatment of cells with AP-1 inhibitor SR-11302 (1 uM). Mean 6 SEM, with *P < 0.05, **P < 0.01 and ***P < 0.001.
response to a pro-calcifying environment takes a central place in the three-step process recently proposed by Shanahan [14] ( Figure 6 ). TNF-a-induced IL-6 production promoted upregulation of typical markers associated with osteochondroblastic transition and oxidative stress, such as RUNX2, ALP, MMP2, COL1/2 and NOX2 [63] [64] [65] , which could be antagonized by blocking ERK/AP-1/c-FOS signalling.
In agreement with Shanahan's [14] proposed interlinkage of viability and calcification, the changes in biomineralization with or without blocking agents of the ERK/AP-1/-c-FOS pathway were paralleled by concomitant changes in VSMC viability in our study. Indeed, VSMC apoptosis and necrosis result in a direct loss of endogenous calcification inhibitors in the vasculature and favor nanocrystal deposition as a nidus for biomineralization.
Blocking with the AP-1 inhibitor SR-11302 resulted in 80% inhibition of IL-6 expression in response to uraemic serum and 50% inhibition in response to TNF-a, indicating that IL-6 induction by TNF-a is mainly mediated by AP-1/c-FOS. This does not contradict but complements the previously documented constitutive involvement of NF-jB signalling in TNF-a-mediated IL-6-induction in VSMCs and osteoblast-like cells [44, 45] .
More importantly, our results demonstrate that uraemic serum-induced calcification of VSMCs is almost entirely blocked in the presence of the AP-1 inhibitor SR-11302 and is strongly inhibited by blocking TNF-a and IL-6 without reducing, but improving, cell viability. Thus our results indicate that the procalcifying activity of uraemic serum is predominantly mediated through AP-1 signalling by reducing IL-6 production.
The transcription factor AP-1 is well known to be involved in the TNF-a receptor signalling pathway [66, 67] , thus enabling TNF-a to influence the expression of many genes. In a previous study we showed how the relative contribution of AP-1 complex subunits (e.g. c-FOS and c-JUN) contributes to the VSMCs subjected to the same treatment conditions as outlined before including anti-TNF-a, anti-IL6 antibody (all 10 ug/mL), or isotype control antibody (all 10 ug/mL), and ERK-inhibitor PD-184352 (100 nM), or AP-1-inhibitor SR-11302 (1000 nM). RUNX2, runt-related transcription factor-2; ALP, alkaline phosphatase tissue-nonspecific isozyme; COL1A1 and COL2A1, collagen type-I and collagen type-II subunit alpha-1; MMP2; matrix metalloproteinase 2; NOX2, cytochrome b-245 beta chain; all transcripts were normalized to a panel of three validated house-keeping genes: B2M, beta-2 microglobulin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; YWHAZ, tyrosine 3-monooxygenase/ tryptophan 5-mono-oxygenase activation protein zeta. (C) Representative western blot for protein expression of RUNX2 (57 kDa), COL2A1 (190 kDa) and GAPDH (37 kDa) following 6-day osteogenic differentiation of VSMCs in the presence of 5% HSP, 5% USP or 5% USP in the presence of anti-TNF-a, anti-IL6 or isotype control antibody (all 10 ug/mL). Mean 6 SEM, with *P < 0.05, **P < 0.01 and ***P < 0.001.
Regulation of VSMC calcification by uraemic serum elaborate control of AP-1 signalling [48, 66] . The novelty of our work presented here is that c-FOS is the key regulatory element within the AP-1 transcription factor complex, since c-JUN was not affected by TNF-a or uraemic serum.
The cascade described here of TNF-a-induced AP-1/c-FOS signalling has recently also been implicated in the process of bronchial hyperreactivity [68] , and selective blockade of TNF-a has previously been shown to be beneficial in this setting. In our experimental model, the selective blockade of TNF-a, IL-6 or AP-1/c-FOS signalling effectively attenuated VSMC calcification, thus emphasizing the importance of each individual step in this process.
Our results may have important clinical implications and support the view that inflammatory mediators could be therapeutic targets to decelerate vascular calcification in dialysis patients [24] . Reducing the immense burden of cardiovascular complications in chronic dialysis with approved anti-inflammatory agents seems a promising new indication. Monoclonal antibodies against TNF-a and IL-6 have already shown promising results in multiple indications with adequate safety.
As a part of this approach, ultrapure dialysates and more biocompatible materials were introduced into haemodialysis procedures [69, 70] , aiming to reduce monocyte activation and pro-inflammatory TNF-a and IL-6 release. We previously analysed the clearance of small and medium-size proinflammatory mediators by high cut-off (HCO) dialysers in the PERCI-I trial [28] . Free TNF-a was not removed better compared with conventional high-flux dialysers, but the concentration of soluble TNF receptors I and II was markedly decreased, potentially contributing to lowering TNF-a, and TNF-a expression in monocytes was significantly reduced after HCO dialysis [71] .
More importantly, 3 weeks of HCO dialysis resulted in a significantly lowered procalcifying activity of uraemic serum [22] . Whether this effect of HCO dialysis was caused by enhanced TNF-a clearance could not be determined at this point. However, the study demonstrated that the dialysed uraemic serum lost its ability to induce both TNF-a mRNA in monocytes and vascular calcification in VSMCs.
Despite these advantages in reducing micro-inflammation and calcification, the long-term use of HCO dialysers for Representative panel of photographs for Alizarin Red S Staining of calcified ECM in culture plates. Mean6SEM, with *P < 0.05, **P < 0.01 and ***P < 0.001. chronic dialysis is limited by a significant loss of albumin. Thus novel medium cut-off dialysers with a steeper cut-off point that can reduce albumin filtration have been introduced [72] , although their efficacy in lowering microinflammation and calcification has yet to be determined. As another therapeutic option, haemodiafiltration has been shown to decrease the production of IL-6 by monocytes [73] , but the effect of haemodiafiltration on mortality is still a matter of intense discussion [25, [74] [75] [76] [77] [78] , as different clinical trials have failed to show any distinct advantages compared with haemodialysis [73, 79] .
C O N C L U S I O N S A N D L I M I T A T I O N S
In summary, our results show that TNF-a plays an important role in uraemia-induced vascular calcification mediated through induction of IL-6 via a c-FOS-dependent pathway, suggesting that therapy options aiming to reduce serum concentrations of TNF-a and TNF receptor superfamily members as well as IL-6 should be investigated in future clinical trials. The limitation of this study is that the mechanistic studies have been performed with well-characterized commercially available VSMCs from a single donor and does not cover interindividual or anatomical variability. Within this context, it would be of great interest to also study these mechanisms in primary isolated VSMCs from donors of different age groups and with different underlying comorbidities. Furthermore, mechanistic validation for VSMCs from different anatomical locations is of great interest.
S U P P L E M E N T A R Y D A T A
Supplementary data are available at ndt online. . This is being initiated by uraemic toxin-mediated damage to the contractile VSMCs that can regulate the vessel tone (top), followed by acquisition of a synthetic VSMC phenotype specialized on adaption and repair (middle), eventually leading to osteochondrocytic VSMCs (e.g. as characterized by induction of RUNX2, ALP and COL1/2). Consequent VSMC apoptosis and necrosis (bottom) results in a loss of endogenous calcification inhibitors (e.g. MGP and fetuin A) upon cell demise in the vasculature, promoting vascular calcification by deposition of nanocrystals, which serve as mineralization nuclei in response to a procalcifying environment with elevated phosphor (P) and calcium (Ca) levels. Although it is well documented that uraemic toxins drive VSMC damage and phenotypic changes promoting vascular calcification, the exact signalling mechanisms underlying this phenomenon are poorly understood to date. We found that TNF-a and IL-6 are key uraemic toxins that mediate calcification of VSMCs through an autocrine amplification loop, involving TNF-a-mediated VSMC-activation to secrete IL-6, via ERK and c-FOS/AP-1-mediated induction of IL-6 expression (right panel). For this purpose, we conducted mechanistic blocking studies at different checkpoints of the TNF-a-IL-6 signalling axis with: (1) anti-TNF-a antibody infliximab (directed towards soluble TNF-a in the uraemic extracellular environment), (2) siRNA against c-FOS (inhibiting c-FOS protein synthesis) and (3) selective pharmacological inhibitors of ERK (PD-184352) and AP-1 (SR-11302), blocking the functional AP-1 complex. We found that apart from a constitutive involvement of the NF-kB-pathway in IL-6 induction, TNF-a is signalling through ERK and the AP-1 transcription factor, with c-FOS being the key regulatory element in formation of the AP-1 transcription factor complex. While c-JUN is abundantly expressed in a constitutive fashion, dynamic regulation of c-FOS provided the key regulatory aspect in formation of the dimeric AP-1 transcription factor complex and consecutive modulation of IL-6 expression in VSMCs. AP-1, activator protein 1; ALP, alkaline phosphatase; COL1/2, collagen type 1/2; ERK, extracellular-signal regulated kinase; MGP, matrix Gla protein; NF-kB, nuclear factor 'kappa-lightchain-enhancer' of activated B-cells; siRNA, small interfering ribonucleic acid; and RUNX2, runt-related transcription factor 2.
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